BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35318440)

  • 1. m
    Tsuchiya K; Yoshimura K; Iwashita Y; Inoue Y; Ohta T; Watanabe H; Yamada H; Kawase A; Tanahashi M; Ogawa H; Funai K; Shinmura K; Suda T; Sugimura H
    Cancer Gene Ther; 2022 Oct; 29(10):1355-1372. PubMed ID: 35318440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N
    Zhu Z; Qian Q; Zhao X; Ma L; Chen P
    Gene; 2020 Mar; 731():144348. PubMed ID: 31927006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. m
    Nagaki Y; Motoyama S; Yamaguchi T; Hoshizaki M; Sato Y; Sato T; Koizumi Y; Wakita A; Kawakita Y; Imai K; Nanjo H; Watanabe H; Imai Y; Minamiya Y; Kuba K
    Genes Cells; 2020 Aug; 25(8):547-561. PubMed ID: 32449584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. m
    Jin D; Guo J; Wu Y; Yang L; Wang X; Du J; Dai J; Chen W; Gong K; Miao S; Li X; Sun H
    Mol Cancer; 2020 Feb; 19(1):40. PubMed ID: 32106857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of AlkB homolog 5 suppresses the progression of non-small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11.
    Huang Z; Lin G; Hong Y; Weng L; Zhu K; Zhuang W
    Environ Toxicol; 2024 Jul; 39(7):4035-4046. PubMed ID: 38642004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA demethylase ALKBH5 inhibits TGF-β-induced EMT by regulating TGF-β/SMAD signaling in non-small cell lung cancer.
    Sun Z; Su Z; Zhou Z; Wang S; Wang Z; Tong X; Li C; Wang Y; Chen X; Lei Z; Zhang HT
    FASEB J; 2022 May; 36(5):e22283. PubMed ID: 35344216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALKBH5 regulates paclitaxel resistance in NSCLC via inhibiting CEMIP-mediated EMT.
    Gao L; Qiao L; Li Y; Jia L; Cui W; Yang J; Wu C; Wang L
    Toxicol Appl Pharmacol; 2024 Feb; 483():116807. PubMed ID: 38199493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages.
    Hua X; Xu Q; Wu R; Sun W; Gu Y; Zhu S; Liu X; Lv T; Song Y
    J Exp Clin Cancer Res; 2024 Jun; 43(1):164. PubMed ID: 38872221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.
    Zhang Z; Wang L; Zhao L; Wang Q; Yang C; Zhang M; Wang B; Jiang K; Ye Y; Wang S; Shen Z
    Clin Transl Med; 2022 Aug; 12(8):e940. PubMed ID: 35979628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALKBH5 regulates cardiomyocyte proliferation and heart regeneration by demethylating the mRNA of YTHDF1.
    Han Z; Wang X; Xu Z; Cao Y; Gong R; Yu Y; Yu Y; Guo X; Liu S; Yu M; Ma W; Zhao Y; Xu J; Li X; Li S; Xu Y; Song R; Xu B; Yang F; Bamba D; Sukhareva N; Lei H; Gao M; Zhang W; Zagidullin N; Zhang Y; Yang B; Pan Z; Cai B
    Theranostics; 2021; 11(6):3000-3016. PubMed ID: 33456585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m
    Tang B; Yang Y; Kang M; Wang Y; Wang Y; Bi Y; He S; Shimamoto F
    Mol Cancer; 2020 Jan; 19(1):3. PubMed ID: 31906946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m
    Zhang L; Su X
    Cell Oncol (Dordr); 2022 Jun; 45(3):355-365. PubMed ID: 35579750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALKBH5 promotes the progression of infantile hemangioma through regulating the NEAT1/miR-378b/FOSL1 axis.
    Peng K; Xia RP; Zhao F; Xiao Y; Ma TD; Li M; Feng Y; Zhou CG
    Mol Cell Biochem; 2022 May; 477(5):1527-1540. PubMed ID: 35182329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. m
    Zhang S; Zhao BS; Zhou A; Lin K; Zheng S; Lu Z; Chen Y; Sulman EP; Xie K; Bögler O; Majumder S; He C; Huang S
    Cancer Cell; 2017 Apr; 31(4):591-606.e6. PubMed ID: 28344040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
    Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
    Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RBM33 is a unique m
    Yu F; Zhu AC; Liu S; Gao B; Wang Y; Khudaverdyan N; Yu C; Wu Q; Jiang Y; Song J; Jin L; He C; Qian Z
    Mol Cell; 2023 Jun; 83(12):2003-2019.e6. PubMed ID: 37257451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m
    Yu T; Yao L; Yin H; Teng Y; Hong M; Wu Q
    Int J Biol Sci; 2022; 18(6):2235-2248. PubMed ID: 35414790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
    Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
    Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
    Yang Z; Cai Z; Yang C; Luo Z; Bao X
    EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K235 acetylation couples with PSPC1 to regulate the m
    Zhang XL; Chen XH; Xu B; Chen M; Zhu S; Meng N; Wang JZ; Zhu H; Chen D; Liu JB; Yan GR
    Nat Commun; 2023 Jun; 14(1):3815. PubMed ID: 37369679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.